請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/65753
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 俞松良(Sung-Liang Yu) | |
dc.contributor.author | Po-Hsiang Kang | en |
dc.contributor.author | 康博翔 | zh_TW |
dc.date.accessioned | 2021-06-17T00:11:06Z | - |
dc.date.available | 2017-09-18 | |
dc.date.copyright | 2012-09-18 | |
dc.date.issued | 2012 | |
dc.date.submitted | 2012-07-13 | |
dc.identifier.citation | 1. Herbst, R.S., J.V. Heymach, and S.M. Lippman, Lung Cancer. New England Journal of Medicine, 2008. 359(13): p. 1367-1380.
2. Cataldo, V.D., et al., Treatment of non-small-cell lung cancer with erlotinib or gefitinib. N Engl J Med, 2011. 364(10): p. 947-55. 3. Pirker, R., Chemotherapy: Advanced NSCLC-should we use doublets in elderly patients? Nat Rev Clin Oncol, 2011. 8(12): p. 694-6. 4. Sharma, S.V., et al., Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer, 2007. 7(3): p. 169-81. 5. Inoue, A., et al., First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol, 2009. 27(9): p. 1394-400. 6. Shepherd, F.A., et al., Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med, 2005. 353(2): p. 123-32. 7. Kim, E.S., et al., Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet, 2008. 372(9652): p. 1809-18. 8. Herbst, R.S., et al., TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol, 2005. 23(25): p. 5892-9. 9. Giaccone, G., et al., Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1. J Clin Oncol, 2004. 22(5): p. 777-84. 10. Kobayashi, S., et al., An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor. Cancer Res, 2005. 65(16): p. 7096-101. 11. Chiang, A.C. and J. Massague, Molecular Basis of Metastasis. New England Journal of Medicine, 2008. 359(26): p. 2814-2823. 12. Gupta, G.P. and J. Massague, Cancer metastasis: building a framework. Cell, 2006. 127(4): p. 679-95. 13. Valastyan, S. and R.A. Weinberg, Tumor metastasis: molecular insights and evolving paradigms. Cell, 2011. 147(2): p. 275-92. 14. Bissell, M.J. and W.C. Hines, Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nat Med, 2011. 17(3): p. 320-9. 15. Valastyan, S. and R.A. Weinberg, MicroRNAs: Crucial multi-tasking components in the complex circuitry of tumor metastasis. Cell Cycle, 2009. 8(21): p. 3506-12. 16. Sonoshita, M., et al., Suppression of colon cancer metastasis by Aes through inhibition of Notch signaling. Cancer Cell, 2011. 19(1): p. 125-37. 17. Giampieri, S., et al., Localized and reversible TGFbeta signalling switches breast cancer cells from cohesive to single cell motility. Nat Cell Biol, 2009. 11(11): p. 1287-96. 18. Stott, S.L., et al., Isolation of circulating tumor cells using a microvortex-generating herringbone-chip. Proc Natl Acad Sci U S A, 2010. 107(43): p. 18392-7. 19. Brown, D.M. and E. Ruoslahti, Metadherin, a cell surface protein in breast tumors that mediates lung metastasis. Cancer Cell, 2004. 5(4): p. 365-74. 20. Al-Mehdi, A.B., et al., Intravascular origin of metastasis from the proliferation of endothelium-attached tumor cells: a new model for metastasis. Nat Med, 2000. 6(1): p. 100-2. 21. Padua, D., et al., TGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell, 2008. 133(1): p. 66-77. 22. Gupta, G.P., et al., Mediators of vascular remodelling co-opted for sequential steps in lung metastasis. Nature, 2007. 446(7137): p. 765-70. 23. Psaila, B. and D. Lyden, The metastatic niche: adapting the foreign soil. Nat Rev Cancer, 2009. 9(4): p. 285-93. 24. Erler, J.T., et al., Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell, 2009. 15(1): p. 35-44. 25. Chambers, A.F., A.C. Groom, and I.C. MacDonald, Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer, 2002. 2(8): p. 563-72. 26. Mazzieri, R., et al., Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells. Cancer Cell, 2011. 19(4): p. 512-26. 27. Chen, H.Y., et al., A five-gene signature and clinical outcome in non-small-cell lung cancer. N Engl J Med, 2007. 356(1): p. 11-20. 28. Chen, J.J., et al., Global analysis of gene expression in invasion by a lung cancer model. Cancer Res, 2001. 61(13): p. 5223-30. 29. Chen, H.W., et al., Curcumin inhibits lung cancer cell invasion and metastasis through the tumor suppressor HLJ1. Cancer Res, 2008. 68(18): p. 7428-38. 30. Ho, C.C., et al., Up-regulated caveolin-1 accentuates the metastasis capability of lung adenocarcinoma by inducing filopodia formation. Am J Pathol, 2002. 161(5): p. 1647-56. 31. Kao, Y.R., et al., Tumor-associated antigen L6 and the invasion of human lung cancer cells. Clin Cancer Res, 2003. 9(7): p. 2807-16. 32. Chang, C.C., et al., Connective tissue growth factor and its role in lung adenocarcinoma invasion and metastasis. J Natl Cancer Inst, 2004. 96(5): p. 364-75. 33. Su, J.L., et al., The VEGF-C/Flt-4 axis promotes invasion and metastasis of cancer cells. Cancer Cell, 2006. 9(3): p. 209-23. 34. Shih, J.Y., et al., Transcription repressor slug promotes carcinoma invasion and predicts outcome of patients with lung adenocarcinoma. Clin Cancer Res, 2005. 11(22): p. 8070-8. 35. Wang, C.C., et al., The transcriptional factor YY1 upregulates the novel invasion suppressor HLJ1 expression and inhibits cancer cell invasion. Oncogene, 2005. 24(25): p. 4081-93. 36. Hong, T.M., et al., Targeting neuropilin 1 as an antitumor strategy in lung cancer. Clin Cancer Res, 2007. 13(16): p. 4759-68. 37. Su, J.L., et al., Knockdown of contactin-1 expression suppresses invasion and metastasis of lung adenocarcinoma. Cancer Res, 2006. 66(5): p. 2553-61. 38. Westbrook, V.A., et al., Spermatid-specific expression of the novel X-linked gene product SPAN-X localized to the nucleus of human spermatozoa. Biol Reprod, 2000. 63(2): p. 469-81. 39. Westbrook, V.A., et al., Differential nuclear localization of the cancer/testis-associated protein, SPAN-X/CTp11, in transfected cells and in 50% of human spermatozoa. Biol Reprod, 2001. 64(1): p. 345-58. 40. Salemi, M., et al., Expression of SPANX proteins in normal prostatic tissue and in prostate cancer. Eur J Histochem, 2010. 54(3): p. e41. 41. Salemi, M., et al., Expression of SPANX proteins in human-ejaculated spermatozoa and sperm precursors. Int J Androl, 2004. 27(3): p. 134-9. 42. Westbrook, V.A., et al., Hominoid-specific SPANXA/D genes demonstrate differential expression in individuals and protein localization to a distinct nuclear envelope domain during spermatid morphogenesis. Mol Hum Reprod, 2006. 12(11): p. 703-16. 43. Wang, Z., et al., Gene expression and immunologic consequence of SPAN-Xb in myeloma and other hematologic malignancies. Blood, 2003. 101(3): p. 955-60. 44. Zendman, A.J., et al., The human SPANX multigene family: genomic organization, alignment and expression in male germ cells and tumor cell lines. Gene, 2003. 309(2): p. 125-33. 45. Westbrook, V.A., et al., Genomic organization, incidence, and localization of the SPAN-x family of cancer-testis antigens in melanoma tumors and cell lines. Clin Cancer Res, 2004. 10(1 Pt 1): p. 101-12. 46. Salemi, M., et al., Expression of SpanX proteins in normal testes and in testicular germ cell tumours. Int J Androl, 2006. 29(2): p. 368-73. 47. Salemi, M., et al., Expression of SpanX mRNA in testicular germ cell tumors. Hum Cell, 2006. 19(3): p. 87-90. 48. Root, D.E., et al., Genome-scale loss-of-function screening with a lentiviral RNAi library. Nat Methods, 2006. 3(9): p. 715-9. 49. Shridhar, R., et al., Cystatin M suppresses the malignant phenotype of human MDA-MB-435S cells. Oncogene, 2004. 23(12): p. 2206-15. 50. Chen, J.J., et al., Up-regulation of tumor interleukin-8 expression by infiltrating macrophages: its correlation with tumor angiogenesis and patient survival in non-small cell lung cancer. Clin Cancer Res, 2003. 9(2): p. 729-37. 51. Chen, Z., et al., Cancer/testis antigens and clinical risk factors for liver metastasis of colorectal cancer: a predictive panel. Dis Colon Rectum, 2010. 53(1): p. 31-8. 52. Klaus, A. and W. Birchmeier, Wnt signalling and its impact on development and cancer. Nat Rev Cancer, 2008. 8(5): p. 387-98. 53. Dai, J., et al., Prostate cancer induces bone metastasis through Wnt-induced bone morphogenetic protein-dependent and independent mechanisms. Cancer Res, 2008. 68(14): p. 5785-94. 54. Tian, E., et al., The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med, 2003. 349(26): p. 2483-94. 55. Nguyen, D.X., et al., WNT/TCF signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis. Cell, 2009. 138(1): p. 51-62. 56. Ng, J.M. and T. Curran, The Hedgehog's tale: developing strategies for targeting cancer. Nat Rev Cancer, 2011. 11(7): p. 493-501. 57. Morris, J.P.t., S.C. Wang, and M. Hebrok, KRAS, Hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma. Nat Rev Cancer, 2010. 10(10): p. 683-95. 58. Mas, C. and A. Ruiz i Altaba, Small molecule modulation of HH-GLI signaling: current leads, trials and tribulations. Biochem Pharmacol, 2010. 80(5): p. 712-23. 59. Sterling, J.A., et al., The hedgehog signaling molecule Gli2 induces parathyroid hormone-related peptide expression and osteolysis in metastatic human breast cancer cells. Cancer Res, 2006. 66(15): p. 7548-53. 60. Pratap, J., et al., Runx2 transcriptional activation of Indian Hedgehog and a downstream bone metastatic pathway in breast cancer cells. Cancer Res, 2008. 68(19): p. 7795-802. 61. Panigrahy, D., et al., Cytochrome P450-derived eicosanoids: the neglected pathway in cancer. Cancer Metastasis Rev, 2010. 29(4): p. 723-35. 62. Wang, D., et al., Prostaglandin E(2) promotes colorectal adenoma growth via transactivation of the nuclear peroxisome proliferator-activated receptor delta. Cancer Cell, 2004. 6(3): p. 285-95. 63. Krysan, K., et al., Prostaglandin E2 activates mitogen-activated protein kinase/Erk pathway signaling and cell proliferation in non-small cell lung cancer cells in an epidermal growth factor receptor-independent manner. Cancer Res, 2005. 65(14): p. 6275-81. 64. Yang, L., et al., Host and direct antitumor effects and profound reduction in tumor metastasis with selective EP4 receptor antagonism. Cancer Res, 2006. 66(19): p. 9665-72. 65. Buchanan, F.G., et al., Role of beta-arrestin 1 in the metastatic progression of colorectal cancer. Proc Natl Acad Sci U S A, 2006. 103(5): p. 1492-7. 66. Han, C., G.K. Michalopoulos, and T. Wu, Prostaglandin E2 receptor EP1 transactivates EGFR/MET receptor tyrosine kinases and enhances invasiveness in human hepatocellular carcinoma cells. J Cell Physiol, 2006. 207(1): p. 261-70. 67. Pai, R., et al., Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat Med, 2002. 8(3): p. 289-93. 68. Ito, H., et al., Prostaglandin E2 enhances pancreatic cancer invasiveness through an Ets-1-dependent induction of matrix metalloproteinase-2. Cancer Res, 2004. 64(20): p. 7439-46. 69. Pan, M.R., et al., Cyclooxygenase-2 up-regulates CCR7 via EP2/EP4 receptor signaling pathways to enhance lymphatic invasion of breast cancer cells. J Biol Chem, 2008. 283(17): p. 11155-63. 70. Steinert, P.M. and D.R. Roop, Molecular and cellular biology of intermediate filaments. Annu Rev Biochem, 1988. 57: p. 593-625. 71. Eckes, B., et al., Impaired mechanical stability, migration and contractile capacity in vimentin-deficient fibroblasts. J Cell Sci, 1998. 111 ( Pt 13): p. 1897-907. 72. Eckes, B., et al., Impaired wound healing in embryonic and adult mice lacking vimentin. J Cell Sci, 2000. 113 ( Pt 13): p. 2455-62. 73. Hong, C.F., et al., MAD2B, a novel TCF4-binding protein, modulates TCF4-mediated epithelial-mesenchymal transdifferentiation. J Biol Chem, 2009. 284(29): p. 19613-22. 74. Imhof, B.A., et al., Cell-cell interaction and polarity of epithelial cells: specific perturbation using a monoclonal antibody. Cell, 1983. 35(3 Pt 2): p. 667-75. 75. Brabletz, T., To differentiate or not - routes towards metastasis. Nat Rev Cancer, 2012. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/65753 | - |
dc.description.abstract | SPANX (Sperm protein associated with the nucleus, X-linked) 此基因家族在睪丸生殖細胞瘤、黑色素瘤、膠質母細胞瘤、惡性血液病中都有高度表現。然而在我們先前Affymetrix基因晶片分析研究中顯示,SPANX family member A1 (SPANXA1) 表現量在低侵襲能力的肺癌細胞株CL 1-0中的表現量較高侵襲能力的細胞株CL 1-5高出97倍,進而以即時定量聚合酶連鎖反應確認SPANXA1信使核醣核酸(mRNA)表現量在CL 1-0比CL 1-5有八倍上升。體外細胞實驗中發現,CL 1-5 SPANXA1穩定表現細胞株和載體穩定表現細胞株相比,其細胞侵襲和移動能力下降跟SPANXA1表現量呈現劑量依賴關係。並且CL 1-5 SPANXA1穩定表現細胞株的細胞形態由本來的間質形態變成表皮形態,呈現典型的反轉表皮間葉細胞轉型過程,而此現象和其侵襲能力下降相吻合。因此我們使用CL 1-5 SPANXA1穩定表現細胞株和載體穩定表現細胞株以鼠尾注射技術來進行體內小鼠腫瘤轉移試驗,結果發現SPANXA1會抑制腫瘤細胞在體內轉移的能力。進一步,我們建立CL 1-0 SPANXA1小髮夾核醣核酸抑制株,在體外實驗中,也可以增加細胞侵襲和移動能力。由於SPANXA1會造成細胞形態改變,我們使用免疫墨點法確認表皮間葉細胞轉型過程標誌的表現,發現在有SPANXA1表現時,表皮型標誌E-cadherin表現上升且間質型標誌N-cadherin和vimentin下降。最後,為了釐清SPANXA1下游可能訊息傳導機制,我們使用Affymetrix 基因晶片來比較CL 1-5 SPANXA1穩定表現細胞株和載體穩定表現細胞株的基因表現差異。實驗結果顯示相關性最高的前十名訊息傳導路徑中,三個路徑都與表皮間葉細胞轉型過程相關,證實表皮間葉細胞轉型過程可能在SPANXA1下游分子機制扮演重要的角色。 | zh_TW |
dc.description.abstract | SPANX (Sperm protein associated with the nucleus, X-linked) gene family has been found higher expression in many cancers, such as testicular germ tumor, melanoma, glioblastoma and hematologic malignancies. However, in our previous study, the gene expression array analysis showed that the expression of SPANX family member A1 (SPANXA1) was up-regulated in lower invasive lung cancer cells, CL 1-0, than in highly invasive cells, CL 1-5. Real-time PCR was used to confirm that mRNA expression of SPANXA1 was 8 times higher in CL 1-0 than CL 1-5. In vitro assays showed that migration and invasion abilities of stably SPANXA1-expressing CL 1-5 transfectants were decreased in a dose-depended manner. Interestingly, cell morphology was dramatically changed from mesenchymal-like to epithelial-like in stably SPANXA1-expressing CL 1-5 transfectants, which was consistent to its decreased invasive ability in vitro. Therefore, we demonstrated metastatic ability of stably SPANXA1-expressing CL 1-5 transfectants would be down-regulated in vivo, which was performed in a mouse metastasis model by tail-vein injection. Next, we set up CL 1-0 lentiviral-base shRNA knockdown clones, and the cell mobility and invasion ability were increased. Because SPANXA1 could induce the cell morphology change, we evaluate the effect of SPANXA1 on the expression of epithelial-mesenchymal transition (EMT) markers. We found up-regulation of E-cadherin, an epithelial marker, and down-regulation of vimentin and N-cadherin, which were known as mesenchymal markers in presence of SPANXA1. Finally, to identify the underlying molecular mechanism of SPANXA1, we carried out gene expression array and 3 of top 10 pathways are EMT-related indicated that EMT pathway might play a major role in SPANXA1-repressed metastasis. | en |
dc.description.provenance | Made available in DSpace on 2021-06-17T00:11:06Z (GMT). No. of bitstreams: 1 ntu-101-R99424007-1.pdf: 4752256 bytes, checksum: fcc54e6e957b5081d56c14fdadb6f7ff (MD5) Previous issue date: 2012 | en |
dc.description.tableofcontents | 口試委員會審定書…………………………..………………………………………..II
致謝………………………………………………………………………………….III 摘要……………………………...…………………………………………………….IV Abstract…………………….………………………………...…….....……………......V 1. Introduction…………………………………………………………………..….....1 1.1 Lung Cancer………………………………………………………………......2 1.1.1 Prevalence and types of Lung Cancer…………………………………...2 1.1.2 Treatment of Lung Cancer……………………………………………….2 1.1.3 Clinical Problems of Lung Cancer………………………………………3 1.2 Metastasis…………………………………………………………………......4 1.2.1 Local Invasion…………………………………………………………4 1.2.2 Intravasation…………………………………………………………...4 1.2.3 Survival in The Circulation……………………………………...………5 1.2.4 Arrest at the distant organ site……………………………………...……5 1.2.5 Extravasation…………………………………………………………….5 1.2.6 Micro-metastasis Formation…………………………………………......6 1.2.7 Metastatic Colonization……………………………………………...…..6 1.3 Microarray…………………………………………………………………….7 1.4 SPANXA1…………………………………………………………………..8 1.4.1 Spermatogenesis of SPANX…………………………………………..8 1.4.2 SPANX in Cancer Research…………………………………………...8 1.4.3 Specific Aims…………………………………………………………....9 2. Materials and Methods…………………………………………………………..10 2.1 Cell Culture…………………………………………………………….......11 2.2 Oligonucleotide Microarray Analysis…………………………………….....11 2.3 Construction of Expression Vector and Stable Transfection…………….….12 2.4 Lentiviral-Based shRNA Package and Infection……………………………13 2.5 Western Blot Analysis……………………………………………………….14 2.6 In Vitro Migration and Matrigel Invasion Assays…………………………...14 2.7 Cell Proliferation Assay…………………………………………………….16 2.8 Single Cell Migration Assay…………………………………………………16 2.9 Anchorage-independent Colony Formation………………………………….17 2.10 Real-time Quantitative RT-PCR……………………………………………17 2.11 In Vivo Metastasis Assay………………………………………………....18 2.12 Statistical Analysis………………………………………………………….19 3. Results…………………………………………………………………...................20 3.1 CL 1-0 SPANXA1 mRNA Expression Is Higher Than That of CL 1-5………………………………………………………………………………....21 3.2 Construction of SPANXA1 Expression Vector and Establishment of Stably SPANXA1-expressed Transfectants………………………………………………...21 3.3 SPANXA1 Inhibits Anchorage-independent Colony Formation but Enhances Proliferation In Vitro……………………………………………………………...22 3.4 SPANXA1 Down-regulates Migration and Invasion Ability in A Dose-dependent Manner In Vitro………………………………………………...…23 3.5 SPANXA1 Suppresses Metastasis In Vivo……………………………… ..24 3.6 Knockdown SPANXA1 Enhances Mobility and Invasion Ability In Vitro.. 24 3.7 SPANXA1 Inhibits Invasion-related Phenotypes in Other Lung Adenocarcinoma Cell Lines…………………………………………………………25 3.8 SPANXA1 Alters EMT-related Cell Morphology and EMT Maker Expression……………………………………………………………………...…27 3.9 Gene Screening of Affymetrx GeneChip and Metacore Pathway Analysis………………………………………………………………………......…27 4. Figures…………...………………………………………………………………29 4.1 Endogenous and Exogenous SPANXA1 Expression……………………...30 4.2 In Vitro Tumorigenicity and Growth Rate of stably SPANXA1-expressing CL 1-5 Transfectants…………………………………………………………….....31 4.3 Invasion-related Phenotypes of stably SPANXA1-expressing CL 1-5 transfectants……………………………………………………………………33 4.4 In Vivo Tail Vein Injection Metastasis Assay……………………………...35 4.5 Phenotypes of TRC Lenti-viral Based shRNA Knockdown System……...36 4.6 SPANXA1-regulated Phenotypes in Lung Adenocarcinoma Cell Lines……38 4.7 EMT-related Morphology and Markers Expression…………………........40 4.8 The Pathway Analysis of Metacore Software……………………………..42 5. Discussion…………………………………………………………………….….43 5.1 SPANXA1 Suppresses Tumor Metastasis………………………………....44 5.2 WNT Pathway in Metastasis………………………………………………44 5.3 Hedgehog Pathway in Metastasis………………………………………….45 5.4 PGE2 Pathway……………………………………………………………..45 5.5 Vimentin Alters Invasion in SPANXA1-overexpressing Cells……………...45 5.6 Slug-E-cadherin Axis Contributes to SPANXA1-suppressed Metastasis…46 6. Appendices…………………………………………………………………..…..48 6.1 Flowchart of Experiment Design…………………………………………..49 6.2 Construction Map of pEF6/V5-His-TOPO-SPANXA1…………………...50 7. References……………………………………………………………………….51 | |
dc.language.iso | en | |
dc.title | SPANXA1經由表皮間葉細胞轉型過程抑制肺癌腫瘤轉移 | zh_TW |
dc.title | SPANXA1 Suppresses Tumor Metastasis through EMT Pathway in Lung Cancer | en |
dc.type | Thesis | |
dc.date.schoolyear | 100-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 陳惠文(Huei-Wen Chen),林亮音(Liang-in Lin),楊雅倩(Ya-Chien Yang) | |
dc.subject.keyword | SPANXA1,肺癌,表皮間葉細胞轉型過程,癌轉移,微陣列基因晶片, | zh_TW |
dc.subject.keyword | SPANXA1,Lung cancer,Metastasis,EMT,Microarray gene chip, | en |
dc.relation.page | 63 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2012-07-13 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 醫學檢驗暨生物技術學研究所 | zh_TW |
顯示於系所單位: | 醫學檢驗暨生物技術學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-101-1.pdf 目前未授權公開取用 | 4.64 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。